Original: IVD, as a high-quality track in the medical field, has a market scale of nearly 100 billion in China, and POCT (point of care testing) is one of the segmentation areas with the largest market potential and imagination space in the IVD industry. In the past five years, with the implementation of policies supporting national brands and hierarchical diagnosis and treatment, the market capacity of POCT industry in China has maintained a rapid growth rate of 15% - 20%, which is far higher than that of IVD industry as a whole. In particular, in recent two years, "micro industry upgrading" has been carried out in POCT field, that is, from luminescence and fluorescence methods of immunochromatography technology platform to microfluidic technology platform Therefore, many POCT enterprises and products based on microfluidic technology have become the focus of medical institutions and capital market. Looking at the emerging enterprises in the field of microfluidic control in China, we find that there are many players in it. However, the author finds that Nanjing Lanyu Biotechnology Co., Ltd. (hereinafter referred to as "Lanyu bio") has made outstanding achievements in the overall technology maturity, industrial landing, product sustainability, cost control and overall upstream and downstream industrial chain control.